10 Stocks Lead Monday’s Charge Amid Market Bloodbath

7. Haleon Plc (NYSE:HLN)

British multinational healthcare firm Haleon Plc rose for a second day on Monday, adding 3.93 percent to close at $10.58 apiece as investors cheered its bullish outlook from an investment firm.

Barclays in a research report on Monday said it maintained a “buy” rating on HLN and set a price target of £4.45.

The upgrade followed a separate coverage from Kepler Capital last week, which also gave HLN a “buy” rating and a price target of £4.25.

Last week, HLN said it achieved a 37-percent increase in its net income attributable to shareholders for full year 2024, ending at £1.44 billion versus £1.05 billion in 2023.

Revenues, however, were lower at £11.2 billion versus £11.3 billion year-on-year.